From the beginning of the COVID-19 pandemic, numerous studies reported the selection of monoclonal antibodies or nanobodies targeting the SARS-CoV-2 RBD [15] with the aim to block RBD-ACE2 interaction and consequently virus entry in permissive epithelial cells [5], [4]. This evidence concerns the gene ACE2 and COVID-19.